Brief: Hisamitsu Pharmaceutical unit assigns rights for Brisdelle Capsules and Pexeva Tablets

Hisamitsu Pharmaceutical Co

26/07/2016 08:12

July 26 (Reuters) - Hisamitsu Pharmaceutical Co Inc 
 4530.T :   
     
    * Says its U.S.-based unit, Noven Pharmaceuticals, Inc., has 
reached agreement to assign rights of approval for manufacture, 
commercialization and associated intellectual property for 
Brisdelle(Paroxetine) Capsules, 7.5 mg and Pexeva(Paroxetine 
Mesylate) Tablets to Sebela International Limited  
     
     
    Source text in Japanese:https://goo.gl/GXA5qi 
    Further company coverage: 4530.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724; 
Reuters Messaging: jun.cao.reuters.com@reuters.net))